WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NBIX

Based on 20 analysts offering 12 month price targets for Neurocrine Biosciences Inc

Min Forecast
$170.00+9.23%
Avg Forecast
$205.50+32.04%
Max Forecast
$253.00+62.55%

Should I buy or sell NBIX stock?

Based on 20 analysts offering ratings for Neurocrine Biosciences Inc.

Strong Buy
Strong Buy
12 analysts 60%
Buy
6 analysts 30%
Hold
2 analysts 10%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NBIX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NBIX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their NBIX stock forecasts and price targets.

NBIX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-03Find Out Why
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-08-03Find Out Why
lockedlocked$00.00+00.00%2026-08-03
lockedlocked$00.00+00.00%2026-08-03Find Out Why
RBC Capital
Top 9%
92
BuyMaintains$198.00+27.22%2026-07-31
TD Cowen
Top 15%
86
Strong BuyMaintains$220.00+41.35%2026-07-31Find out why
Piper Sandler
Top 4%
97
Strong BuyMaintains$210.00+34.93%2026-07-31Find out why
Cantor Fitzgerald
Top 2%
99
Strong BuyMaintains$215.00+38.14%2026-07-31Find out why
Guggenheim
Top 2%
99
Strong BuyMaintains$222.00+42.64%2026-07-31Find out why

1 of 2

Forecast return on equity

Is NBIX forecast to generate an efficient return?

Company
50.56%
Industry
61.54%
Market
167.6%
NBIX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NBIX forecast to generate an efficient return on assets?

Company
34.85%
Industry
23.58%
NBIX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NBIX earnings per share forecast

What is NBIX's earnings per share in the next 3 years based on estimates from 31 analysts?

Avg 1 year Forecast
$7.16+1.61%
Avg 2 year Forecast
$10.39+47.44%
Avg 3 year Forecast
$13.31+88.72%
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NBIX revenue forecast

What is NBIX's revenue in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$4.0B+17.93%
Avg 2 year Forecast
$4.6B+36.99%
Avg 3 year Forecast
$5.2B+53.86%
NBIX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NBIX earnings growth forecast

How is NBIX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
23.77%
Industry
18.23%
Market
31.05%
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NBIX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NBIX revenue growth forecast

How is NBIX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
15.55%
Industry
10.58%
Market
13.43%
NBIX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NBIX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NBIX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
NBIX$155.64$205.50+32.04%Strong Buy
VTRS$16.88$20.00+18.48%Strong Buy
ELAN$24.50$30.33+23.81%Strong Buy
RDY$11.97N/AN/A
ALKS$46.10$57.36+24.43%Buy
View Top Pharmaceutical Stocks

Neurocrine Biosciences Stock Forecast FAQ

Is Neurocrine Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 20 Wall Street analysts covering (NASDAQ: NBIX) stock is to Strong Buy NBIX stock.

Out of 20 analysts, 12 (60%) are recommending NBIX as a Strong Buy, 6 (30%) are recommending NBIX as a Buy, 2 (10%) are recommending NBIX as a Hold, 0 (0%) are recommending NBIX as a Sell, and 0 (0%) are recommending NBIX as a Strong Sell.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

What is NBIX's earnings growth forecast for 2026-2028?

(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual earnings growth rate of 23.77% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 18.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.05%.

Neurocrine Biosciences's earnings in 2026 is $705,500,000.On average, 31 Wall Street analysts forecast NBIX's earnings for 2026 to be $728,153,743, with the lowest NBIX earnings forecast at $557,850,705, and the highest NBIX earnings forecast at $822,900,945. On average, 30 Wall Street analysts forecast NBIX's earnings for 2027 to be $1,056,602,577, with the lowest NBIX earnings forecast at $665,436,198, and the highest NBIX earnings forecast at $1,634,061,409.

In 2028, NBIX is forecast to generate $1,352,442,353 in earnings, with the lowest earnings forecast at $912,484,368 and the highest earnings forecast at $2,105,815,258.

What is NBIX's revenue growth forecast for 2026-2028?

(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 15.55% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.58%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.43%.

Neurocrine Biosciences's revenue in 2026 is $3,373,900,000.On average, 32 Wall Street analysts forecast NBIX's revenue for 2026 to be $404,462,091,199, with the lowest NBIX revenue forecast at $382,607,517,284, and the highest NBIX revenue forecast at $434,245,301,232. On average, 31 Wall Street analysts forecast NBIX's revenue for 2027 to be $469,822,514,582, with the lowest NBIX revenue forecast at $405,986,828,914, and the highest NBIX revenue forecast at $558,358,951,233.

In 2028, NBIX is forecast to generate $527,660,898,571 in revenue, with the lowest revenue forecast at $470,839,006,392 and the highest revenue forecast at $631,546,361,553.

What is NBIX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NBIX) forecast ROA is 34.85%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 23.58%.

What is NBIX's Price Target?

According to 20 Wall Street analysts that have issued a 1 year NBIX price target, the average NBIX price target is $205.50, with the highest NBIX stock price forecast at $253.00 and the lowest NBIX stock price forecast at $170.00.

On average, Wall Street analysts predict that Neurocrine Biosciences's share price could reach $205.50 by Sep 3, 2027. The average Neurocrine Biosciences stock price prediction forecasts a potential upside of 32.04% from the current NBIX share price of $155.64.

What is NBIX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NBIX) Neurocrine Biosciences's current Earnings Per Share (EPS) is $7.05. On average, analysts forecast that NBIX's EPS will be $7.16 for 2026, with the lowest EPS forecast at $5.49, and the highest EPS forecast at $8.10. On average, analysts forecast that NBIX's EPS will be $10.39 for 2027, with the lowest EPS forecast at $6.55, and the highest EPS forecast at $16.08. In 2028, NBIX's EPS is forecast to hit $13.31 (min: $8.98, max: $20.72).

What is NBIX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NBIX) forecast ROE is 50.56%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.